Will Cumberland Pharmaceuticals stock go up?

According to Danelfin AI, Cumberland Pharmaceuticals has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (50.50%) is -0.32% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Cumberland Pharmaceuticals stock?

The Cumberland Pharmaceuticals target price is $6.39 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Cumberland Pharmaceuticals stock right now?

Cumberland Pharmaceuticals has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (50.50%) is -0.32% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Cumberland Pharmaceuticals stock is a good buy .

Is Cumberland Pharmaceuticals undervalued right now?

Based on analysts, the average price target downside for Cumberland Pharmaceuticals is 0.00% (1Y). According to Danelfin AI, Cumberland Pharmaceuticals has today an AI Score of 4/10 (Hold Rating).

What was the price range of Cumberland Pharmaceuticals stock over the past 12 months?

The Cumberland Pharmaceuticals stock price range over the past 12 months has been $1.9 - $7.13.

What is going on with Cumberland Pharmaceuticals stock in the last 3 months?

The Cumberland Pharmaceuticals stock performance in the last quarter has been +106.12%.

Does Cumberland Pharmaceuticals offer dividend payments?

No, Cumberland Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals's market cap is $95.44M, as of 2026-07-03 08:00.

Cumberland Pharmaceuticals Inc (CPIX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CPIX AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Cumberland Pharmaceuticals Inc today receives an AI Score of 4/10, which translates to a Hold rating. The stock has a 51% probability of outperforming the market in the next 3 months, which is equal to the average probability of any stock (51%). Key positive contributors include the Fear & Greed Index (currently at 31, indicating fear) boosting probability by +0.29%, the Plus Directional Indicator (+DI, 90d) in the top 10% adding +0.28%, and Gross Margin in the top 20% contributing +0.21%. On the negative side, the Fundamentals Impact (Long Tail) detracts -0.40%, the Technicals Impact (Long Tail) detracts -0.30%, and the Pharmaceuticals industry detracts -0.28%. Notable data points include a Gross Margin of 78.82% (top 20%), indicating strong profitability, and a Plus Directional Indicator (+DI, 90d) of 29.76 (top 10%), signaling strong buying pressure. However, the stock has a negative Alpha Last Day of -0.10 (bottom 10%), underperforming the market recently, and Earnings Countdown of -52 days (bottom 20%), meaning earnings were reported over a month ago. The Operating Profit Margin is -34.27% (bottom 30%), reflecting operational losses. Overall, the mixed signals—positive technicals and margins offset by weak fundamentals and industry headwinds—result in a neutral Hold rating, with the stock's probability of outperforming the market exactly at the average.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Size & Liquidity+0.36%
Company size and trading liquidity
Profitability+0.33%
Profitability and operating efficiency metrics
Volatility+0.01%
How much the stock price tends to fluctuate

Momentum-0.68%
Direction and strength of recent price movements
Sentiment-0.14%
How analysts and the market view the stock
Valuation-0.10%
How the stock is priced relative to its fundamentals
Earnings Quality-0.10%
Stability and reliability of reported earnings

CPIX probability advantage of beating the market (3M):

-0.32%

Technical

Cumberland Pharmaceuticals (CPIX) has a Technical Score of 7/10 because, according to only technical analysis, it has a probability advantage of +3.61% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.73%) and the probability of CPIX (54.34%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.73%
CPIX probability advantage of beating the market (only technical, 3M)+3.61%
CPIX probability of beating the market (3M)54.34%

CPIX probability advantage of beating the market (only technical, 3M): +3.61%

The AI-powered technical analysis of Cumberland Pharmaceuticals (CPIX) is only based on the 30 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CPIX:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	+1.46%
Technical	Upgrade to Pro to unlock	+0.91%
Technical	Upgrade to Pro to unlock	+0.80%
Technical	Upgrade to Pro to unlock	-0.60%
Technical	Upgrade to Pro to unlock	+0.60%
Technical	Upgrade to Pro to unlock	+0.58%
Technical	Upgrade to Pro to unlock	+0.53%
Technical	Upgrade to Pro to unlock	-0.50%
Technical	Upgrade to Pro to unlock	-0.44%
Technical	Upgrade to Pro to unlock	-0.41%
Technical	Upgrade to Pro to unlock	-0.38%
Technical	Upgrade to Pro to unlock	+0.33%
Technical	Upgrade to Pro to unlock	-0.33%
Technical	Upgrade to Pro to unlock	+0.30%
Technical	Upgrade to Pro to unlock	+0.27%

Rest of Alpha Signals: +0.49%

CPIX probability advantage of beating the market (only technical, 3M)Total:+3.61%
CPIX Technical Score

Significant changes Vs previous day

CPIX Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$6.39
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

CPIX Proven Hold Signal & Price Forecast

This is the price chart for CPIX from January 2, 2026 until today. The chart indicates, in yellow, the 113 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CPIX Average Past Performance & Win Rate

Three months after its 1506 Hold signals since July 2026, CPIX had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1506 Past CPIX Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+3.77%
Average Alpha				-10.55%
Win Rate (% Positive Perf.)				24.11%
% Positive Alpha				20.08%

CPIX Frequently Asked Questions

Will Cumberland Pharmaceuticals stock go up?
According to Danelfin AI, Cumberland Pharmaceuticals has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (50.50%) is -0.32% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Cumberland Pharmaceuticals stock?
Is it a good time to buy, sell, or hold Cumberland Pharmaceuticals stock right now?
Is Cumberland Pharmaceuticals undervalued right now?
What was the price range of Cumberland Pharmaceuticals stock over the past 12 months?
What is going on with Cumberland Pharmaceuticals stock in the last 3 months?
Does Cumberland Pharmaceuticals offer dividend payments?
What is the current market capitalization of Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals Inc Company Profile

Cumberland Pharmaceuticals Inc. operates as a specialty pharmaceutical corporation with an emphasis on procuring, cultivating, and bringing to market prescription medicine used in hospital acute care, gastroenterology, and oncology in the U.S. and across the globe. The company provides several distinct products including Acetadote, an injection administered for acetaminophen poisoning cases; Caldolor captures the market for pain and fever relief; Kristalose is included for constipation treatment plans owing to its properties as a prescription laxative oral solution.

Additionally, Omeclamox-Pak functions as a remedy for Helicobacter pylori infection along with duodenal ulcer conditions while Vaprisol is available as an injection to balance out euvolemic and hypervolemic hyponatremia cases. Sancuso injectable serves chemotherapy patients whereas Vibativ brings relief amidst certain severe bacterial infections that encompass hospital-acquired pneumonia, ventilator-associated bacterial pneumonia along with intricate skin structure infections.

The pharmaceutical firm is also underway in terms of developing RediTrex which acts as decisive treatment against active rheumatoid, juvenile idiopathic arthritis including formidable psoriasis cases. Furthermore, Cumberland has ventured into creating ifetroban—a product under phase II clinical tests designed to cure aspirin-exacerbated respiratory disorder plus systemic sclerosis notwithstanding duchenne muscular dystrophy.

Apart from having finished phase II tests for treating hepatorenal syndrome alongside portal hypertension issues—there's also progressive development in regard to devising clinical programs centered around utilizing ifetroban for addressing progressive fibrosing interstitial lung diseases. The roots of this progressively innovative company trace back to 1999 when it was established—it currently stations its headquarters in Nashville, Tennessee.

Sector:Health Care
Country:United States
Industry:Pharmaceuticals
Address:1600 West End Avenue, Suite 1300, Nashville
Employees:93
Website:cumberlandpharma.com

Pros

Established portfolio of commercialized pharmaceutical products

Intellectual property protection for proprietary formulations

Specialized distribution network for hospital-based therapies

Operating leverage from existing manufacturing infrastructure

Potential for inorganic growth through product acquisitions

Cons

Revenue dependency on a narrow product offering

Vulnerability to patent expiration and generic entry

High regulatory approval risk for pipeline assets

Exposure to pharmaceutical pricing pressure from payers

Capital requirements for clinical development programs

CPIX Stock AI Analysis